Insights and news
Stephenson Harwood advises Shield Therapeutics plc on exclusive Japan licence
Law firm Stephenson Harwood LLP has advised Shield Therapeutics plc on its exclusive licence agreement with VITAL-NET, Inc. for ACCRUFeR® in Japan.
Stephenson Harwood advises GE Healthcare on transformative Zionexa acquisition
Law firm Stephenson Harwood LLP has advised GE Healthcare on the acquisition of Zionexa. GE Healthcare is a medical technology, pharmaceutical diagnostics, and digital solutions company; Zionexa is an innovator of in-vivo oncology and neurology biomarkers that help enable more personalised healthcare.
Partner Alexandra Pygall joins Babraham Institute Board
Stephenson Harwood partner Alexandra Pygall has been appointed to The Babraham Institute’s Board of Trustees.
Stephenson Harwood advises Acacia Pharma on €27 million fundraise
Law firm Stephenson Harwood LLP has advised Acacia Pharma Group plc on its successful €27 million fundraise, through the placing of 10 million new ordinary shares with institutional investors in Europe and the US.
Stephenson Harwood advises Schroder UK Public Private Trust on £49 million asset sale
Law firm Stephenson Harwood LLP has acted for Schroder UK Public Private Trust plc (SUPP) on an agreement for the £49 million sale of seven portfolio assets to Rosetta Capital VI, LP, an investment fund managed by the UK-based life science venture capital firm Rosetta Capital Limited.
Stephenson Harwood advises Oxford Biomedica on gene therapy collaboration
Law firm Stephenson Harwood LLP has advised gene and cell therapy company Oxford Biomedica on its collaboration with biopharmaceutical company PhoreMost, to develop next-generation CAR-T cell therapies.
Stephenson Harwood advises capiton on KD Pharma single-asset secondary
Law firm Stephenson Harwood LLP has advised private equity firm capiton on a general partner-led single asset secondary transaction relating to the KD Pharma Group.
Stephenson Harwood advises Oxford Biomedica on COVID-19 vaccine with AstraZeneca
Law firm Stephenson Harwood LLP has advised Oxford Biomedica plc (Oxford Biomedica), a gene and cell therapy company, on a Clinical and Commercial Supply Agreement with AstraZeneca UK Ltd (AstraZeneca).
